StockIQpro
NASDAQ:MBRX

Moleculin Biotech, Inc.

Track all markets on TradingView
Track all markets on TradingView

Moleculin Biotech, Inc.'s revenue was $0 in fiscal 2025. Free cash flow was −$22.7M.Summary generated from Moleculin Biotech, Inc.'s SEC filings. Latest annual report filed Mar 18, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−256.0%
Debt / equityn/a
Free cash flow−$22.7M
FCF marginn/a
Share count changen/a

Financials

Fiscal years, $M
Item20212022202320242025
Revenue00000
Operating income−23−31−30−27−25
Net income−16−29−30−26−34
Free cash flow−19−28−24−24−23

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations